Related Experiment Video
Updated: Jul 11, 2026
06:38
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis
D A Sica1, T Comstock, A Harford
1Department of Medicine, Medical College of Virginia, Richmond.
European Journal of Clinical Pharmacology
|January 1, 1987
Summary
This study investigated ranitidine pharmacokinetics in patients on continuous ambulatory peritoneal dialysis (CAPD). Results inform a proposed dosing regimen for ranitidine in this patient population.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Pharmacy
Background:
- Renal impairment significantly alters drug pharmacokinetics.
- Continuous ambulatory peritoneal dialysis (CAPD) is a common renal replacement therapy.
- Understanding ranitidine disposition in CAPD patients is crucial for safe and effective dosing.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of ranitidine in patients undergoing CAPD.
- To determine ranitidine clearance and bioavailability during CAPD.
- To propose a modified dosing regimen for ranitidine in CAPD patients.
Main Methods:
- Six CAPD patients received either 50 mg intravenous or 150 mg oral ranitidine HCl on separate occasions.
- Plasma concentrations were measured over time to determine pharmacokinetic parameters.
- Peritoneal and renal clearances were assessed, along with drug removal via dialysis.
Main Results:
- Ranitidine followed a two-compartment model with first-order elimination after IV administration.
- Mean bioavailability was 69.7% following oral administration.
- Peritoneal clearance was 3.2 mL/min (IV) and 2.6 mL/min (oral); significant drug removal occurred via dialysis.
Conclusions:
- Ranitidine exhibits altered pharmacokinetics in CAPD patients.
- A proposed dosage regimen aims to optimize ranitidine therapy in this population.
- Further studies may refine dosing recommendations based on individual patient characteristics.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...